# Progress Note 04 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Leonard Nimoy (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML017-SYN
- Date: 2026-08-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Carla Benedetti, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month COPD review. **S**

## History of present illness

Mr. Nimoy returns for his six-month COPD review. He has kept up the home exercise program, walking about 15 minutes twice a day and doing his strength routine three times a week. He still walks about 300 meters before stopping and uses a wheelchair for long distances such as airports. He uses albuterol about twice a week and takes every maintenance dose. He has had no flare-up, antibiotic or prednisone course, emergency visit, or hospital stay since he started treatment. The summer heat made him more breathless on a few afternoons, and he walked in the early morning instead. **S**

| Element | Detail |
|---|---|
| Exercise | Home program kept up; walks about 300 meters before stopping |
| Reliever use | Albuterol about twice a week |
| Adherence | All maintenance doses taken |
| Exacerbations | None in six months of treatment, and none in the past 12 months |
| Triggers | Hot afternoons; walks early in the day |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Breathless after about 300 meters or a flight of stairs; little cough; no change in sputum |
| Cardiovascular | Negative | No chest pain, palpitations, or ankle swelling |
| Psychiatric | Negative | Mood good |

3 systems reviewed. **S**

## Current medications

- Albuterol 90 mcg/actuation inhaler, two inhalations as needed for breathlessness (prescribed by his previous clinician; used once or twice most days before intake) **S**
- Tiotropium-olodaterol 2.5/2.5 mcg soft mist inhaler, two inhalations once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/74 mmHg; pulse 76 bpm; respirations 18/min; temperature 36.6 °C; oxygen saturation 94% on room air; weight 81 kg; BMI 23.7 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Comfortable at rest |
| Lungs | Reduced breath sounds with prolonged expiration; no wheeze or crackles |
| Cardiovascular | Regular rhythm at 76 per minute; no edema |
| Inhaler technique | Correct with his soft mist inhaler |

All examination findings are synthetic. **S**

## Assessment and plan

1. **COPD, GOLD 3, group B, stable** (J44.9). CAT 14 and mMRC grade 2, with no exacerbation in six months; resting saturation 94 percent. The gains from rehabilitation have held. No change in treatment is needed. **S**
   - Continue tiotropium-olodaterol and albuterol as needed.
   - Continue the home exercise program, walking in the cooler part of the day.
   - High-dose influenza and RSV vaccines at the annual wellness visit in October.
   - Yearly spirometry at the February review.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | COPD Assessment Test (CAT) | Every visit | Completed today | 14, stable |
| Survey | mMRC dyspnea grade | Every visit | Completed today | Grade 2, stable |
| Survey | Exacerbation history and GOLD group | Every visit | Completed today | None in the past 12 months; group B |
| Examination | Pulse oximetry | Every visit | Completed today | 94 percent at rest on room air |
| Self-management | Smoking status and cessation support | Every visit | Completed today | Former smoker; no tobacco |
| Examination | BMI and nutritional status | Every visit | Completed today | BMI 23.7; weight stable |
| Examination | Inhaler technique and adherence | Every visit | Completed today | Correct; full adherence |
| Examination | Long-term oxygen assessment | As indicated: resting saturation 88 percent or less, confirmed twice at least three weeks apart | Not indicated | Resting saturation 94 percent |
| Referral | Pulmonary rehabilitation | Eligibility reviewed yearly and after any hospital stay | Up to date | Completed in May; home program kept up |
| Examination | Spirometry | At diagnosis, then at least yearly and with significant clinical change | Up to date | Due at the yearly review in February |
| Survey | Mood and comorbidity screening | At diagnosis and yearly | Due | Due at the annual wellness visit in October |
| Medication safety | Vaccination status | Reviewed yearly | Due | Influenza and RSV vaccines planned for the annual wellness visit before the respiratory virus season; COVID-19 vaccine this autumn |

## Goal progress

- CAT score at least 2 points lower by the three-month review. Outcome by 2026-05-12: CAT fell from 22 to 15. **S**
- 6-minute walk distance at least 30 meters farther after pulmonary rehabilitation. Outcome by 2026-05-12: 270 m at entry and 330 m at exit. **S**
- No moderate or severe exacerbation over the six months after starting maintenance therapy. Outcome by 2026-08-11: No exacerbation, oral corticosteroid course, antibiotic course, or emergency visit in six months. **S**
- Correct soft mist inhaler technique and a daily maintenance dose. Outcome by 2026-03-10: Correct technique on demonstration and no missed doses by dose counter at four weeks. **S**

## Guideline basis

- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025), Global Initiative for Chronic Obstructive Lung Disease
- CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026), Aether Forge
- Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023), American Thoracic Society (Am J Respir Crit Care Med 2023;208(4):e7-e26)
- Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020), American Thoracic Society (Am J Respir Crit Care Med 2020;202(10):e121-e141)
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Annual wellness visit in October. COPD review in about six months with spirometry, or the same day for any flare-up. **S**
- Next scheduled visit 2026-10-06: subsequent annual wellness visit. **S**
